EMR20066-007


Protocolnummer:

Ziekenhuizen:
Universitair Medisch Centrum Groningen
Universitair Medisch Centrum Utrecht

Titel:
A multicentre, open label, randomized phase ll trial of the MEK inhibitor pimasertib or dacarbazine in previously untreated subjects with NRAS mutated locally advanced or metastatic malignant cutaneous melanoma

Behandeling:
Pimasertib 60 mg BID vs. Dacarbazine IV

Stadium:
Stadium irresectable IIIc/IV

Belangrijkste in/exclusiecriteria:
In: Histologically of cytologically confirmed locally advanced or metastatic cutaneous melanoma (stage lllc or M1ac) N-Ras mutated, N-RAS mutational status must be prospectively defined before inclusion. Ex: previous sytemic treatment (excluding adjuvant treatment), non-measurable lesions, ECOG PS>1, bone marrow impairment, renal impairment, history of difficulty swallowing, malabsorption or other chronic gastro-intestinal disease.

Contactpersoon:

Alle trials